Medicus Pharma (MDCX): Reporting 800,952 Shares — 4.5% Stake

Medicus Pharma Ltd. Schedule 13G/A reports that SkinJect Partners LLC directly owns 800,952 common shares of Medicus Pharma, representing 4.5% of the outstanding common stock based on 17,816,266 shares reported by the company.

Rhea-AI Filing Summary

Medicus Pharma Ltd. Schedule 13G/A reports that SkinJect Partners LLC directly owns 800,952 common shares of Medicus Pharma, representing 4.5% of the outstanding common stock based on 17,816,266 shares reported by the company. The filing shows SkinJect Partners has sole voting and sole dispositive power over these shares.

John Hathaway is identified as a reporting person and may be deemed the beneficial owner of the shares held by SkinJect Partners LLC, though he disclaims beneficial ownership except to the extent of any direct ownership. The filing provides standard disclosure of ownership and power to vote or dispose.

Insights

Securities Analyst

TL;DR Reporting shows a 4.5% stake held by SkinJect Partners LLC; ownership appears non-controlling and routine.

The Schedule 13G/A discloses that SkinJect Partners LLC directly holds 800,952 shares and has sole voting and dispositive power. The position is under the 5% threshold generally considered a significant block for control changes, so this disclosure is primarily informational. The report clarifies beneficial ownership attribution to John Hathaway while also noting his disclaimer, which is common when individuals control entities that hold shares. For investors, the filing documents ownership concentration but does not indicate a change in control or a new strategic transaction.

Corporate Governance Expert

TL;DR Ownership disclosure is transparent; the 4.5% stake is material to monitor but not indicative of control.

The filing properly identifies both the entity owner and the natural person associated with that entity, including the standard disclaimer of direct beneficial ownership by John Hathaway. Sole voting and dispositive powers are reported for the shares, which is important for governance records. Because the stake is below 5%, it falls into routine reporting territory rather than triggering heightened regulatory or takeover concerns. The joint filing agreement is incorporated by reference, consistent with coordinated reporting practices.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Medicus Pharma (MDCX) shares does SkinJect Partners LLC report owning?

The filing reports 800,952 shares held directly by SkinJect Partners LLC, representing 4.5% of the outstanding common stock.

Does John Hathaway claim beneficial ownership of the shares reported in the MDCX filing?

John Hathaway is named as a reporting person and may be deemed the beneficial owner of the shares held by SkinJect Partners LLC, but he disclaims beneficial ownership except to the extent of any direct ownership.

What voting and dispositive power is reported for the shares in this MDCX filing?

The filing states sole voting power: 800,952 and sole dispositive power: 800,952, with no shared voting or dispositive power.

Is the reported stake in Medicus Pharma above the 5% disclosure threshold?

No. The reported stake is 4.5%, which is below the 5% level commonly viewed as a higher-significance ownership threshold.

On what share count is the 4.5% ownership percentage based?

The percentage is calculated using an aggregate of 17,816,266 common shares outstanding as reported by the company in its quarterly report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2025 - 09:00 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Medicus Pharma Ltd.

(Name of Issuer)

Common shares, no par value

(Title of Class of Securities)

58471K202

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 58471K202

1

Names of Reporting Persons

John Hathaway

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 800,952.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 800,952.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

800,952.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Consists of 800,952 held by SkinJect Partners LLC, an entity controlled by John Hathaway. John Hathaway may be deemed the beneficial owner of securities held by SkinJect Partners LLC. John Hathaway disclaims beneficial ownership of such securities except to the extent of his direct ownership.

SCHEDULE 13G

CUSIP No. 58471K202

1

Names of Reporting Persons

SkinJect Partners LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 800,952.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 800,952.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

800,952.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Medicus Pharma Ltd.
(b)	Address of issuer's principal executive offices: 300 Conshohocken State Road, Suite 200, W. Conshohocken, PA 19428
Item 2.
(a)	Name of person filing: This statement is being filed on behalf of each of the following persons (collectively, the "Reporting Persons"): (i) John Hathaway; and (ii) SkinJect Partners LLC.
(b)	Address or principal business office or, if none, residence: The principal business address of each of the Reporting Persons is as follows: 285 Kappa Drive, Suite 100 Pittsburgh, PA 15238
(c)	Citizenship: See Row (4) of each Reporting Person's cover page.
(d)	Title of class of securities: Common shares, no par value
(e)	CUSIP No.: 58471K202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: SkinJect Partners LLC, an entity controlled by John Hathaway, directly owns 800,952 common shares of Medicus Pharma Ltd. (the "Company"). John Hathaway may be deemed the beneficial owner of securities held by SkinJect Partners LLC. John Hathaway disclaims beneficial ownership of such securities except to the extent of his direct ownership.
(b)	Percent of class: See Row (11) of each Reporting Person's cover page. The percentages used herein are calculated based upon on aggregate of 17,816,266 common shares reported by the Company to be outstanding as of August 11, 2025, as reflected in the Company's Quarterly Report on Form 10-Q filed on August 11, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row (5) of each Reporting Person's cover page.
	(ii) Shared power to vote or to direct the vote: See Row (6) of each Reporting Person's cover page.
	(iii) Sole power to dispose or to direct the disposition of: See Row (7) of each Reporting Person's cover page.
	(iv) Shared power to dispose or to direct the disposition of: See Row (8) of each Reporting Person's cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

John Hathaway

Signature:	/s/ John Hathaway
Name/Title:	John Hathaway
Date:	08/12/2025

SkinJect Partners LLC

Signature:	/s/ John Hathaway
Name/Title:	John Hathaway, Managing Director
Date:	08/12/2025

Exhibit Information

Exhibit 99.1: Joint Filing Agreement (previously filed as Exhibit 99.1 to the Schedule 13G filed on February 10, 2025, and incorporated herein by reference).